Tissue-based biomarkers, such as microvessel density, pericyte coverage, and the expression of angiogenesis-related genes, provide direct evidence of VEGFR-targeted therapy’s impact on the tumor vasculature and also warrant exploration [96]. Here, KDR is linked to neoplasm.